Pharma Diagnostic Consulting

Pharma Diagnostic ConsultingPharma Diagnostic ConsultingPharma Diagnostic Consulting

Pharma Diagnostic Consulting

Pharma Diagnostic ConsultingPharma Diagnostic ConsultingPharma Diagnostic Consulting
  • Home
  • Services
  • Contact Us
  • More
    • Home
    • Services
    • Contact Us
  • Home
  • Services
  • Contact Us

Experienced Pharmaceutical and Diagnostics Consulting

Experienced Pharmaceutical and Diagnostics ConsultingExperienced Pharmaceutical and Diagnostics ConsultingExperienced Pharmaceutical and Diagnostics Consulting

Helping you design success!

Book Online

Experienced Pharmaceutical and Diagnostics Consulting

Experienced Pharmaceutical and Diagnostics ConsultingExperienced Pharmaceutical and Diagnostics ConsultingExperienced Pharmaceutical and Diagnostics Consulting

Helping you design success!

Book Online

Welcome

Have a look around and learn all there is to know about us. Take a moment to drop us a line so we can talk about next steps.

Find out more

Linkedin Profile: www.linkedin.com/in/eric-lai-ph-d-9277546

Our Experience

Dr. Eric Lai is Managing Officer at Pharma-Dx, LLC and currently a team lead with the NIH COVID-19 Rapid Acceleration of Diagnostics (RADx) Initiative.  For almost 30 years, Dr. Lai has focused his efforts in the clinical application of Pharmacogenomics in drug development and drug safety, from discovery to bedside. Before retirement in 2018, Dr. Eric Lai was Senior Vice President and Head of Genomic Medicine at Takeda Pharmaceutical.  Before he joined Takeda, he was the SVP and Head of Research and Development at Gen-Probe (now part of Hologic Inc) from 2009 – 2012 and before that he was the VP of Pharmacogenetics at GlaxoSmithKline for over 13 years.   Dr. Lai received his Ph.D., from Columbia University and did his post-doctoral training at Dr. Lee Hood’s laboratory at Caltech in the early days of the Human Genome Project.  He was the co-scientific leader of The SNP Consortium and the Severe Adverse Reaction Consortium. In 2002, Dr. Lai discovered the association of HLA5701 to Abacavir hypersensitivity reaction and oversaw the clinical development and application of this test.  The Abacavir HLA5701 discovery significantly improved the benefit-risk relationship by identifying patients at high risk for a serious drug adverse reaction and is frequently quoted in FDA guidance as one of the most important demonstrations of genomic medicine. 

What We Do

All About You

The Technical Stuff

The Technical Stuff

Your business is our business. We believe in making your dreams and goals a reality and our experts know just how to do that. We're prepared to help you at any level, from impartial advice or practical assistance to help you make the most of every opportunity. 

The Technical Stuff

The Technical Stuff

The Technical Stuff

Whether you're just starting out or looking to restructure we've got you covered. Our mantra is: analyze, identify, advise, execute. Our mission is to create relationships, not transactions. Our promise is that we'll be there, as questions or issues arise, every step of the way. 

Our Expertise

The Technical Stuff

Our Expertise

We're a group of scientists and strategists that thrive on sharing our experience and knowledge to help you make a success of your business. Our track record of over 20 years in drug and IVD development  will be critical to your success

Subscribe

Podcast

Copyright © 2022 Pharma Diagnostic Consulting - All Rights Reserved.

Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept